Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: ARL2

Gene summary for ARL2

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

ARL2

Gene ID

402

Gene nameADP ribosylation factor like GTPase 2
Gene AliasARFL2
Cytomap11q13.1
Gene Typeprotein-coding
GO ID

GO:0000226

UniProtAcc

P36404


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
402ARL2HTA11_3410_2000001011HumanColorectumAD5.30e-051.28e-010.0155
402ARL2HTA11_2487_2000001011HumanColorectumSER1.65e-072.15e-01-0.1808
402ARL2HTA11_1938_2000001011HumanColorectumAD6.59e-072.21e-01-0.0811
402ARL2HTA11_78_2000001011HumanColorectumAD2.35e-061.98e-01-0.1088
402ARL2HTA11_347_2000001011HumanColorectumAD3.42e-163.08e-01-0.1954
402ARL2HTA11_2112_2000001011HumanColorectumSER1.29e-053.67e-01-0.2196
402ARL2HTA11_3361_2000001011HumanColorectumAD1.09e-062.67e-01-0.1207
402ARL2HTA11_83_2000001011HumanColorectumSER5.74e-082.58e-01-0.1526
402ARL2HTA11_696_2000001011HumanColorectumAD7.11e-142.80e-01-0.1464
402ARL2HTA11_866_2000001011HumanColorectumAD2.07e-071.97e-01-0.1001
402ARL2HTA11_1391_2000001011HumanColorectumAD1.53e-174.04e-01-0.059
402ARL2HTA11_2992_2000001011HumanColorectumSER2.31e-084.22e-01-0.1706
402ARL2HTA11_5212_2000001011HumanColorectumAD5.12e-053.01e-01-0.2061
402ARL2HTA11_5216_2000001011HumanColorectumSER3.34e-042.80e-01-0.1462
402ARL2HTA11_546_2000001011HumanColorectumAD4.83e-083.04e-01-0.0842
402ARL2HTA11_866_3004761011HumanColorectumAD1.77e-133.19e-010.096
402ARL2HTA11_9408_2000001011HumanColorectumAD6.03e-054.36e-010.0451
402ARL2HTA11_8622_2000001021HumanColorectumSER1.49e-062.87e-010.0528
402ARL2HTA11_7663_2000001011HumanColorectumSER7.76e-084.07e-010.0131
402ARL2HTA11_10623_2000001011HumanColorectumAD4.46e-062.63e-01-0.0177
Page: 1 2 3 4 5 6 7 8 9 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EndometriumThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AEH: Atypical endometrial hyperplasia
EEC: Endometrioid Cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0046034ColorectumADATP metabolic process142/3918277/187232.64e-298.26e-26142
GO:0006091ColorectumADgeneration of precursor metabolites and energy209/3918490/187233.17e-286.61e-25209
GO:0009060ColorectumADaerobic respiration108/3918189/187239.14e-281.43e-24108
GO:0045333ColorectumADcellular respiration119/3918230/187233.21e-254.02e-22119
GO:0015980ColorectumADenergy derivation by oxidation of organic compounds143/3918318/187232.78e-222.49e-19143
GO:0009150ColorectumADpurine ribonucleotide metabolic process142/3918368/187234.29e-151.17e-12142
GO:0006163ColorectumADpurine nucleotide metabolic process149/3918396/187231.08e-142.80e-12149
GO:0072521ColorectumADpurine-containing compound metabolic process153/3918416/187234.34e-141.01e-11153
GO:0009259ColorectumADribonucleotide metabolic process144/3918385/187235.25e-141.13e-11144
GO:0019693ColorectumADribose phosphate metabolic process145/3918396/187233.01e-135.71e-11145
GO:1902903ColorectumADregulation of supramolecular fiber organization139/3918383/187232.01e-123.19e-10139
GO:0009117ColorectumADnucleotide metabolic process168/3918489/187232.20e-123.36e-10168
GO:0006753ColorectumADnucleoside phosphate metabolic process169/3918497/187234.99e-126.98e-10169
GO:0032271ColorectumADregulation of protein polymerization94/3918233/187231.01e-111.29e-0994
GO:0051258ColorectumADprotein polymerization112/3918297/187231.85e-112.27e-09112
GO:0043254ColorectumADregulation of protein-containing complex assembly148/3918428/187232.64e-113.18e-09148
GO:1902905ColorectumADpositive regulation of supramolecular fiber organization85/3918209/187235.95e-116.33e-0985
GO:0051495ColorectumADpositive regulation of cytoskeleton organization89/3918226/187231.61e-101.56e-0889
GO:0032273ColorectumADpositive regulation of protein polymerization62/3918138/187231.94e-101.76e-0862
GO:0031334ColorectumADpositive regulation of protein-containing complex assembly91/3918237/187234.78e-103.99e-0891
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
ARL2SNVMissense_Mutationc.221G>Tp.Arg74Leup.R74LP36404protein_codingdeleterious(0)probably_damaging(1)TCGA-A2-A0YE-01Breastbreast invasive carcinomaFemale<65I/IIUnspecificTaxotereSD
ARL2SNVMissense_Mutationrs766982672c.280G>Ap.Ala94Thrp.A94TP36404protein_codingtolerated(0.64)benign(0.011)TCGA-C5-A1BF-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinPD
ARL2SNVMissense_Mutationrs146832019c.443G>Ap.Arg148Hisp.R148HP36404protein_codingdeleterious(0.04)benign(0.001)TCGA-AZ-4315-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
ARL2SNVMissense_Mutationc.409N>Ap.Ala137Thrp.A137TP36404protein_codingdeleterious(0.04)benign(0.003)TCGA-AZ-6598-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
ARL2SNVMissense_Mutationrs746518542c.124G>Ap.Asp42Asnp.D42NP36404protein_codingtolerated(0.47)benign(0.007)TCGA-EI-6917-01Colorectumrectum adenocarcinomaMale<65III/IVChemotherapy5fluorouracil+oxaciplatina+l-folinianSD
ARL2SNVMissense_Mutationnovelc.140C>Tp.Thr47Metp.T47MP36404protein_codingdeleterious(0.02)probably_damaging(0.941)TCGA-AJ-A3BH-01Endometriumuterine corpus endometrioid carcinomaFemaleUnknownI/IIUnknownUnknownSD
ARL2SNVMissense_Mutationrs748651201c.221N>Ap.Arg74Glnp.R74QP36404protein_codingdeleterious(0)probably_damaging(1)TCGA-AJ-A8CV-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
ARL2SNVMissense_Mutationrs778402408c.310N>Tp.Arg104Trpp.R104WP36404protein_codingdeleterious(0.02)benign(0.022)TCGA-AP-A1DV-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
ARL2SNVMissense_Mutationrs758628032c.475G>Ap.Ala159Thrp.A159TP36404protein_codingdeleterious(0.02)probably_damaging(0.963)TCGA-AX-A06F-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinSD
ARL2SNVMissense_Mutationrs779164260c.394G>Ap.Ala132Thrp.A132TP36404protein_codingdeleterious(0)possibly_damaging(0.903)TCGA-AX-A0IZ-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
Page: 1 2 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1